Health officials have quietly scrubbed claims that over 100 hospital trusts were actively using the controversial Federated Data Platform. The incident raises fresh questions about the government's £330 million contract with the US tech giant amid growing pressure to trigger a break clause.
An Erosion of Trust
NHS England has been forced into an embarrassing retreat this week after deleting a widely cited claim that 137 hospital trusts were successfully utilising Palantir’s Federated Data Platform (FDP). The retraction follows an investigation revealing that at least 29 of those trusts—nearly a quarter of the total figure cited—were not actually employing the technology at all. The discrepancy, exposed after mounting pressure from transparency advocates, serves as the latest flashpoint in an increasingly fractious debate over the role of US-based data giants in the nation’s health service.
The Shadow of the FDP
The £330 million contract awarded to the American software powerhouse Palantir remains one of the most contentious procurement decisions in recent NHS history. Despite a concerted outcry from cross-party MPs, clinical leaders, and patient advocacy groups calling for the activation of a critical break clause, reports suggest the government is preparing to extend the arrangement for a further two years. Critics argue that the FDP, which is designed to integrate fragmented patient data, is being pushed upon trusts as a mandatory standard rather than as a solution tailored to specific local needs.
Displacing Proven Systems
The controversy is not merely administrative; it is deeply rooted in the clinical front line. Several industry suppliers have alleged that the FDP is being used to replace more capable, established systems such as SHREWD, which has long been the gold standard for hospital flow management. The concern among frontline staff is that the push for the Palantir system is motivated by a desire for centralised control rather than actual operational efficiency. Some hospital managers have suggested that the transition is being framed as a cost-cutting exercise, effectively forcing trusts to abandon bespoke tools that staff have spent years mastering in favour of a 'one-size-fits-all' model that may lack the granular functionality required to manage complex hospital wards.
Questionable Performance Metrics
This is not the first time NHS England has been rebuked for its promotion of the platform. The Office for Statistics Regulation previously issued a warning, noting that the health service lacked sufficient, robust evidence to substantiate its internal claims that the FDP was directly responsible for performance improvements. The regulation body has cautioned that without clear, objective data, it is impossible for the public to discern whether the investment is yielding tangible benefits for patients or if it is simply a case of expensive digital theatre. Furthermore, recent Freedom of Information requests have shed light on the intense lobbying efforts undertaken by Palantir to expand its influence, particularly into the sensitive realm of GP patient records. These revelations have deepened anxiety regarding data sovereignty and the ultimate direction of the digitisation strategy under the current government.
The Road Ahead
As the debate intensifies, health unions are preparing to demand a full parliamentary inquiry into the contract's milestones. With the two-year extension looming, the burden of proof rests heavily on NHS England to demonstrate that the FDP is delivering value for money. For now, the credibility of the project remains bruised by the recent admission of inflated engagement figures, leaving many to wonder whether the platform will become an enduring pillar of the NHS or a costly error in central planning.
